Investors are regenerating their interest in Regeneron Pharmaceuticals
Under the new terms of the deal, Sanofi will increase its pre-clinical funding of the partnership from $100 million to $160 million per year starting next year and extend it for five more years. The two-year-old partnership has already produced four antibody-based drugs that are in clinical trials and a fifth that is awaiting clearance by the Food and Drug Administration. The companies are hoping to raise that number to four to five drugs per year, which is rather astounding. If they can hit that level through 2017 -- when the partnership ends -- there's a pretty good chance of a product making it to market, assuming the average failure rate in the clinic.
And once the drugs make it into the clinic, Regeneron has a pretty sweet deal. It retains 50% of the profits, but unlike Exelixis'
Sanofi owns a little more than 19% of Regeneron stock, but don't expect the French giant to buy its partner anytime soon. The companies have a standstill agreement that caps Sanofi's ownership at 25% through late 2011 and 30% after that.
While the deal is good for Regeneron and the stock certainly deserves a bump on the news, much of the value of the $1.5 billion company still resides in its late-stage pipeline. It has one drug, Arcalyst, for sale in an ultra-orphan indication that now has competition from Novartis
The extended partnership is a good fallback plan, but, for better or worse, the value of Regeneron's stock is still tied to the results of clinical trials expected next year.
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Novartis is a Global Gains recommendation. The Fool owns shares of Exelixis and has a disclosure policy.
More from The Motley Fool
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
An immuno-oncology drug that's in the works could generate significant revenue growth someday.
3 High-Yield Dividend Stocks to Buy in 2018
These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.
This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November
Shareholders aren't seeing too clearly after this double-dose of news concerning lead drug Eylea.